Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer

Authors:

Abstract
Locally advanced non–small cell lung cancer (NSCLC) accounts for 20% to 25% of new diagnoses of NSCLC.1 The historical 5-year overall survival rate for definitive concurrent chemoradiotherapy for locally advanced NSCLC was 25% to 30%.2-4 Recently, consolidative programmed death ligand-1 (PD-L1) inhibition using durvalumab after chemoradiotherapy improved progression-free survival (PFS) and 3-year overall survival to 57.0% compared with 43.5% for chemoradiotherapy alone.5,6

This publication has 28 references indexed in Scilit: